Hjem › Endometriekreft › Oklahoma › Oklahoma City
Kliniske studier for Endometriekreft i Oklahoma City, OK
25 studier for Endometriekreft søker deltakere på steder i og rundt Oklahoma City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- University of Oklahoma, Oklahoma City
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RekruttererFase 1
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RekruttererFase 1/2
- Stephenson Cancer Center, Oklahoma City
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- University of Oklahoma, Oklahoma City
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RekruttererFase 3
- Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RekruttererFase 3
- Research Site, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RekruttererFase 1
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RekruttererFase 2
- Stephenson Cancer Center at OU Health, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruttererFase 1
- Normunity Investigational Site, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Stephenson Cancer Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
RekruttererObservasjonsstudie
- Mercy Hospital - OKC, Oklahoma City
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RekruttererFase 1/2
- University of Oklahoma Health Stephenson Cancer Center, Oklahoma City
Uterine Preservation Via Lifestyle Transformation
RekruttererFase 2
- University of Oklahoma, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RekruttererFase 1
- Dren Investigational Site, Oklahoma City
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RekruttererFase 1
- University of Oklahoma, Oklahoma City
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RekruttererFase 2
- Oklahoma University Stephenson Cancer Center, Oklahoma City
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RekruttererFase 2
- University of Oklahoma, Oklahoma City
Endometriekreft-studier i andre byer
- Houston, TX68 studier
- New York City, NY52 studier
- Boston, MA50 studier
- Arlington, VA39 studier
- Nashville, TN38 studier
- Los Angeles, CA34 studier
- St. Louis, MO29 studier
- Philadelphia, PA28 studier
- San Antonio, TX27 studier
- Columbus, OH25 studier
- Chicago, IL25 studier
- Queens, NY25 studier
Andre studier i Oklahoma City
- Ikke-småcellet lungekreft28 studier
- Eggstokkreft28 studier
- Kolorektal kreft22 studier
- Prostatakreft21 studier
- Lungekreft19 studier
- Brystkreft17 studier
- Metastatisk kreft16 studier
- Kreft (alle typer)14 studier
- Akut myelogen leukemi14 studier
- Plateepitelcancer i hode og hals13 studier
- Blærekreft11 studier
- Pankreaskreft11 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.